Hosted on MSN1mon
Regeneron projects EYLEA HD growth with new approvals and prefilled syringe launch in 2025CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent, Libtayo, and EYLEA HD. He emphasized the acceleration in EYLEA HD uptake expected ...
Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD).
LONDON, GREATER LONDON, UNITED KINGDOM, January 24, 2025 /EINPresswire / -- What's the Growth Trajectory of the Eylea HD Market in Recent and Upcoming Years? The eylea HD market has shown immense ...
The Business Research Company's Eylea HD Global market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback